Close

Articles Posted in Pharmaceutical defect cases

Updated:

Illinois Appellate Court Affirms $18.5 Million Medical Malpractice Verdict and Remands the Case for Further Disposition Against Drug Company

Angie Muhammad had been receiving treatment at Northwestern Memorial Hospital since December 2003. She was hospitalized four times between January and May 2005 with psychotic symptoms. In May 2005, she was prescribed Depakote as a mood stabilizer. She became pregnant. After being advised by her physician, she discontinued using Depakote…

Updated:

Illinois Appellate Court Finds That Physician and Pharmacy Have No Duty to Warn of Medical Risks Associated With Long-Term Use of Reglan

The plaintiff, Stephan Urbaniak,was prescribed and took a drug called Reglan for six years. He developed severe movement disorders. The prescribing physician, Dr. John Ross, admits that he was unaware of the risk of developing these movement disorders from long-term use of this prescription drug. By operation of the “learned…

Updated:

State Supreme Court Affirms Dismissal of Lawsuit Against Bayer Corp. for Lack of Personal Jurisdiction

In following the U.S. Supreme Court’s decisions in Daimlar AG v. Bauman, 134 S. Ct. 746 (2014) and BNSF Railway Company v. Tyrrleo, 137 S. Ct. 1549 (2017) and the Missouri Court’s earlier opinion in State ex rel. Norfolk S. Ry. Co. v. Dolan, 512 S.W. 3d 41 (Mo. En…

Updated:

U.S. Supreme Court Prevents Out-of-State Resident Plaintiffs from Joining Pharmaceutical Defect (Plavix) Lawsuit

The U.S. Supreme Court has prevented 592 nonresidents from joining 86 California residents in suing Bristol-Myers Squibb in California state court for personal injury allegedly caused by Plavix, a blood thinner. At the state level, the California Supreme Court concluded that the Due Process Clause of the 14th Amendment did…

Updated:

U.S. District Court Orders Disclosure by Plaintiffs’ Counsel of Pre-deposition Contacts

In Illinois it is well-settled law that prohibits defendants and their lawyers from communicating with treating physicians without the consent of the patient. In this case, plaintiffs sued five pharmaceutical companies in federal court where it was claimed they were injured by testosterone-replacement products. In this multidistrict litigation case, one…

Updated:

$124 Million Penalty to Stand Against the Drug Maker Janssen for the Drug Risperdal

The U.S. Supreme Court says it will not hear an appeal from Johnson & Johnson’s subsidiary, Janssen, which had been penalized $124 million for deceptive marketing of its anti-psychotic drug, Risperdal. The federal district court has entered a ruling that Janssen Pharmaceuticals Inc. should pay penalties for violating South Carolina…

Updated:

Xarelto Lawsuits are Underway in Multi-district Litigation in the U.S. District Court for the Eastern District of Louisiana

More than 25 lawsuits have been filed against Johnson & Johnson subsidiaries, Janssen Pharmaceuticals and Bayer Corporation, in consolidated cases in the Louisiana federal district court regarding the serious side effects of the blood-thinning drug, Xarelto. Xarelto has been associated with serious side effects, including internal bleeding, gastrointestinal bleeding, brain…

Contact Us